Literature DB >> 20694189

Preparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2.

Qian-Sheng Yu1, Weiming Luo, Jeffery Deschamps, Harold W Holloway, Theresa Kopajtic, Jonathan L Katz, Arnold Brossi, Nigel H Greig.   

Abstract

As a clinical medication for the treatment of hyperkinetic movement disorders, in conditions such as Huntington's disease, tetrabenazine (TBZ) has been always used in its racemic form. To establish whether or not its beneficial therapeutic actions are enantiospecific, a practical total synthetic route was developed to yield each enantiomeric form to allow their chemical and pharmacological characterization. We briefly summarize the total synthesis of TBZ and report a detailed procedure for resolution of TBZ into its enantiomers, (+)-TBZ and (-)-TBZ. This allowed determination of the optical rotation and absolute configurations of each TBZ enantiomer, based on X-ray crystallographic analysis, together with characterization of their inhibitory action at the vesicular monoamine transporter 2, where (+)-TBZ proved three-fold more active than (-)-TBZ.

Entities:  

Year:  2010        PMID: 20694189      PMCID: PMC2915582          DOI: 10.1021/ml1000189

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  15 in total

1.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  The long-term effect of tetrabenazine in the management of Huntington disease.

Authors:  Alfonso Fasano; Federica Cadeddu; Arianna Guidubaldi; Carla Piano; Francesco Soleti; Paola Zinzi; Anna Rita Bentivoglio
Journal:  Clin Neuropharmacol       Date:  2008 Nov-Dec       Impact factor: 1.592

3.  Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport.

Authors:  D S Thiriot; A E Ruoho
Journal:  J Biol Chem       Date:  2001-05-24       Impact factor: 5.157

Review 4.  Role of monoamine transporters in mediating psychostimulant effects.

Authors:  Evan L Riddle; Annette E Fleckenstein; Glen R Hanson
Journal:  AAPS J       Date:  2005-12-20       Impact factor: 4.009

5.  Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.

Authors:  Christopher Kenney; Christine Hunter; Joseph Jankovic
Journal:  Mov Disord       Date:  2007-01-15       Impact factor: 10.338

Review 6.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

7.  Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine.

Authors:  D Scherman; P Jaudon; J P Henry
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

8.  Asymmetric synthesis of tetrabenazine and dihydrotetrabenazine.

Authors:  Michael J Rishel; Kande K D Amarasinghe; Sean R Dinn; Bruce F Johnson
Journal:  J Org Chem       Date:  2009-05-15       Impact factor: 4.354

9.  Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Sairam Krishnamurthy; Seth Norrholm; Gabriela Deaciuc; Kiran B Siripurapu; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-23       Impact factor: 4.030

Review 10.  Tetrabenazine in the treatment of hyperkinetic movement disorders.

Authors:  Christopher Kenney; Joseph Jankovic
Journal:  Expert Rev Neurother       Date:  2006-01       Impact factor: 4.618

View more
  5 in total

1.  Accelerating the semisynthesis of alkaloid-based drugs through metabolic engineering.

Authors:  Amy M Ehrenworth; Pamela Peralta-Yahya
Journal:  Nat Chem Biol       Date:  2017-02-15       Impact factor: 15.040

2.  Derivatization of (±) dihydrotetrabenazine for copper-64 labeling towards long-lived radiotracers for PET imaging of the vesicular monoamine transporter 2.

Authors:  Amit Kumar; Su-Tang Lo; Orhan K Öz; Xiankai Sun
Journal:  Bioorg Med Chem Lett       Date:  2014-10-28       Impact factor: 2.823

3.  Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.

Authors:  Zhangyu Yao; Xueying Wei; Xiaoming Wu; Jonathan L Katz; Theresa Kopajtic; Nigel H Greig; Hongbin Sun
Journal:  Eur J Med Chem       Date:  2011-02-23       Impact factor: 6.514

4.  Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis.

Authors:  Lindsey R Orgren; Emily E Maverick; Christopher C Marvin
Journal:  J Org Chem       Date:  2015-11-13       Impact factor: 4.354

Review 5.  Synthesis of Tetrabenazine and Its Derivatives, Pursuing Efficiency and Selectivity.

Authors:  Seung-Mann Paek
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.